Skip to main content
. 2022 Feb 28;10(3):376. doi: 10.3390/vaccines10030376

Table 1.

Patient characteristics.

CD (n = 104) UC (n = 40) p
Gender (% Male) 46 (44.2%) 18 (45%) 0.934
Montreal classification
B1 69 (66.3%) E1 4 (10%)
B2 23 (22.1%) E2 12 (30%)
B3 12 (11.5%) E3 20 (50%)
perianal
disease
21 (20.2%) colectomy 4 (10%)
IBD disease severity
Remission/Asymptomatic 17 (16.3%) 12 (30%) p < 0.001
S1—Mild 51 (49%) 6 (15%)
S2—Moderate 25 (24%) 10 (25%)
S3—Severe 11 (10.6%) 8 (20%)